An analysis carried out by Novartis Romania highlights the long delays in Romanian patients' access to innovative medicines, with an average of 460 days from the approval of compensation by the ANMDM. Oncology is the most affected, with 40% of the indications analyzed. Although the assessment process has improved, the compensation steps remain lengthy. The study emphasizes the need for reforms in the reimbursement system to ensure rapid and equitable access to treatment.
Sources
Studiu: Pacienţii români aşteaptă, în medie, 460 de zile ca să primească medicamentele inovatoare compensate/ Aproximativ 40% din totalul indicaţiilor terapeutice analizate au fost de natură oncologică
Studiu: Pacienţii români aşteaptă, în medie, 460 de zile ca să primească medicamentele inovatoare compensate / Aproximativ 40% din totalul indicaţiilor terapeutice analizate au fost de natură oncologică
Studiu: Pacienţii români aşteaptă, în medie, 460 de zile ca să primească medicamentele inovatoare compensate / Aproximativ 40% din totalul indicaţiilor terapeutice analizate au fost de natură oncologică
Latest News
17:53
The Ministry of Finance has informed the Government that Romania's public debt has reached 60.1% of GDP
17:49
Researchers have developed extremely small nanorobots capable of interacting with bacteria and individual cells
17:41
Russians withdrew nearly 3.4 billion dollars from banks in August, amid fears that they could be blocked and used to finance the war.
17:35
The Ministry of Energy denies the information according to which large industrial consumers have received notifications to limit energy consumption.
17:30
A 59-year-old woman from Oradea won the largest prize in the history of Loto 6/49, worth 10 million euros.
See more news